source,title,authors,abstract,publication_date,url,id,journal,doi,affiliations
PubMed,A left-sided incarcerated Amyand hernia in a 4-month-old male infant: a case report.,Roya Golmoradi Pilehroud; Alireza Ziyabakhsh; Keyvan Amini; Reza Panahizadeh; Mohammadamin Vatankhah; Hamed Mohammadi Haris,"Amyand hernias are inguinal hernias that involve the vermiform appendix and are very rare. Left-sided Amyand hernias are even rarer, and their diagnosis is often made intraoperatively.",2025-Jul-08,https://pubmed.ncbi.nlm.nih.gov/40629422/,40629422,Journal of medical case reports,10.1186/s13256-025-05394-w,"Department of Surgery, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.; Students Research Committee, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.; Department of Surgery, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.; Cancer Immunology and Immunotherapy Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.; Radiology Department, Tabriz University of Medical Sciences, Tabriz, Iran.; Division of Vascular and Endovascular Surgery, Department of Surgery, Shohada-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. hamedmharis@gmail.com."
PubMed,Gut microbiome changes and cancer immunotherapy outcomes associated with dietary interventions: a systematic review of preclinical and clinical evidence.,Csenge Somodi; David Dora; Mátyás Horváth; Gabor Szegvari; Zoltan Lohinai,"Cancer patient's survival has gradually improved due to immune checkpoint inhibitors (ICIs). Several studies showed a possible association between the intestinal microbiome and ICI efficacy. Strategies for modifying the composition of the gut microbiome encompass various dietary interventions, which may have distinct impacts on the outcomes of ICI-treated patients. In our systematic review, we explored how dietary habits correlate with therapeutic responses in cancer patients and cancer mouse models undergoing immunotherapy.",2025-Jul-08,https://pubmed.ncbi.nlm.nih.gov/40629403/,40629403,Journal of translational medicine,10.1186/s12967-025-06586-0,"Translational Medicine Institute, Semmelweis University, Tűzoltó Utca 37-47, 1094, Budapest, Hungary.; Department of Anatomy, Histology, and Embryology, Semmelweis University, Budapest, Hungary.; Translational Medicine Institute, Semmelweis University, Tűzoltó Utca 37-47, 1094, Budapest, Hungary.; Translational Medicine Institute, Semmelweis University, Tűzoltó Utca 37-47, 1094, Budapest, Hungary.; Translational Medicine Institute, Semmelweis University, Tűzoltó Utca 37-47, 1094, Budapest, Hungary. lohinai.zoltan@semmelweis.hu."
PubMed,Post-translational modifications of cancer immune checkpoints: mechanisms and therapeutic strategies.,Haiqing Jia; Lei Jiang; Xiaoyu Shen; Huinan Ye; Xinguang Li; Liwei Zhang; Yanyan Hu; Dandan Song; Hui Jia; Zhe Wang,"Immunotherapies, particularly immune checkpoint inhibitors (ICIs), have revolutionized cancer clinical management, but low response rates and treatment resistance remain challenging. Protein post-translational modifications (PTMs) are critical for governing protein expression, localization, functions, and interactions with other cellular molecules, which notably build up the diversity and complexity of the proteome. A growing body of evidence supports that PTMs influence immunotherapy efficacy and outcomes by post-translationally modulating the expression and functions of immune checkpoints. Therefore, understanding the PTM mechanisms that govern immune checkpoints is paramount for developing novel treatment strategies to improve immunotherapy efficacy and overcome resistance. This review provides an overview of the current comprehension of the regulatory mechanisms by which PTMs (glycosylation, phosphorylation, ubiquitination, acetylation, succinylation, palmitoylation, lactylation, O-GlcNAcylation, UFMylation, and neddylation) modulate immune checkpoints to unveil potential therapeutic targets. Moreover, this review discusses the potential of therapeutic strategies targeting PTMs of immune checkpoints, providing insights into the combination treatment with ICIs in maximizing the benefits of immunotherapy and overcoming resistance.",2025-Jul-08,https://pubmed.ncbi.nlm.nih.gov/40629335/,40629335,Molecular cancer,10.1186/s12943-025-02397-5,"Department of Gynecology Surgery 1, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, 110042, China.; Department of Breast Medicine 1, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang,, Liaoning, 110042, China.; Department of Thoracic Medicine 2, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, 110042, China.; Department of Digestive Diseases 1, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, 110042, China.; Department of General Surgery, Fuxin Central Hospital, Fuxin, Liaoning, 123100, China.; Department of Vascular Interventional Therapy, General Hospital of Northern Theater Command, Shenyang, Liaoning, 110016, China.; Department of Digestive Diseases 1, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, 110042, China. 13704025442@163.com.; Department of Respiratory and Critical Care Medicine, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, China. songdandan1986@126.com.; Department of Anesthesiology, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, China. jh_selina945@126.com.; Department of Digestive Diseases 1, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, 110042, China. wangzhe@cmu.edu.cn."
PubMed,Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective.,Negar Sadat Sherafat; Ali Keshavarz; Amirhossein Mardi; Amirmohammad Mohammadiara; Mojtaba Aghaei; Leili Aghebati-Maleki; Mohammad Hossein Mohammadi,"Combination of immune checkpoint inhibitors (ICIs) and anti-angiogenic drugs (AADs) holds promise in cancer treatment. While ICIs block signals that help cancer cells evade the immune system, anti-angiogenic agents target blood vessels, limiting tumor growth by restricting nutrient and oxygen supplies. Additionally, the judicious use of AADs can normalize the tumor vasculature, alleviate hypoxia, and enhance the antitumor immune response. As the shutdown of a single target does not necessarily eradicate cancer, the use of combinations of molecular-targeted agents has been proposed, and some pioneering research has been conducted to examine the efficacy of this strategy. The combination of these two modalities offers a synergistic approach, enhancing the efficacy of tumor eradication. Recent studies have elucidated the rationale behind this combination therapy, but a limited response rate has been achieved with monotherapy. Clinical trials have demonstrated the potential of this combination, with improved outcomes in various solid tumor types. The dual blockade of angiogenesis and immune checkpoints is poised to become a standard of care, with indications expected to expand as more evidence accumulates. The antitumor efficacy of current therapies is limited, most likely because of the high degree of cancer clonal heterogeneity, intratumor genetic heterogeneity, and cell signal complexity. Although numerous studies have been conducted in this area, this review provides a comprehensive analysis of the molecular rationale for ICIs and AADs in cancer therapy. We not only compare the individual properties and mechanisms of both treatments, but also explore their complementary roles, which are essential for optimizing personalized treatment strategies. By addressing key challenges such as tumor heterogeneity, immune evasion, and resistance to monotherapies, we demonstrate how this combination approach can enhance treatment outcomes. Furthermore, we incorporate the latest preclinical and clinical findings and offer future perspectives on optimizing drug selection, dosing, and treatment design to maximize therapeutic efficacy.",2025-Jul-08,https://pubmed.ncbi.nlm.nih.gov/40629032/,40629032,Clinical and experimental medicine,10.1007/s10238-025-01751-7,"Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.; Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.; Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.; Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Leili_aghebati_maleki@yahoo.com.; Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Drmohammadi@sbmu.ac.ir."
PubMed,Intratumoral expression of IL-12 and CD40 ligand (CD154) from plasmids generates antitumor responses that eliminate tumoral T regs.,Gregory W Ho; Alicia Santos; Jennifer Fields; Pamela C Rosato; Mary Jo Turk; Nicole F Steinmetz; Steven Fiering,"Intratumoral immunotherapy (ITIT) strives to generate effective antitumor immunity by directly stimulating the immune system in tumors to reverse local tumor-mediated immune suppression. In vivo expression of Interleukin-12 (IL-12) using in vivo plasmid transfection as an intratumoral cancer immunotherapy entered Phase II clinical trials for metastatic melanoma but to limited clinical success. We sought to improve the efficacy of in vivo IL-12 electroporation by the addition of a CD154 (CD40 ligand)- expressing plasmid to the IL-12 encoding plasmid treatment and assessing efficacy against solid tumors. Mice with intradermal B16F10 melanoma or MC38 murine colon carcinoma tumors received 2 weekly intratumoral (IT) injections of plasmids encoding IL-12 and CD154, followed by in vivo electroporation. The addition of CD154 to IL-12 was superior to IL-12 alone and resulted in frequent tumor clearance of treated tumors, marked by an increase in CD8 T cells and a drastic reduction in T regulatory cells in the tumor microenvironment. Tumor treatment responses were abrogated in mice which lack conventional DC1 cells (BatF3 KO) or lack CD8 T cells. These findings highlight the potential of adding CD154 to IL-12 plasmid electroporation as a cancer immunotherapy and suggest that other combinations would be therapeutically valuable.",2025-Jul-08,https://pubmed.ncbi.nlm.nih.gov/40628928/,40628928,Scientific reports,10.1038/s41598-025-09535-5,"Department of Microbiology and Immunology, Dartmouth Geisel School of Medicine, Hanover, NH, 03755, USA.; Department of Microbiology and Immunology, Dartmouth Geisel School of Medicine, Hanover, NH, 03755, USA.; Department of Microbiology and Immunology, Dartmouth Geisel School of Medicine, Hanover, NH, 03755, USA.; Department of Microbiology and Immunology, Dartmouth Geisel School of Medicine, Hanover, NH, 03755, USA.; Department of Microbiology and Immunology, Dartmouth Geisel School of Medicine, Hanover, NH, 03755, USA.; Aiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, 9500 Gilman Dr., La Jolla, CA, 92093, USA.; Department of Microbiology and Immunology, Dartmouth Geisel School of Medicine, Hanover, NH, 03755, USA. fiering@dartmouth.edu."
PubMed,Cancer Research in the 21st Century: Recent Advances and Future Perspectives.,Vrushali P Patole; Nirmala V Shinde; Siddhi M Chandak; Ashwini T Satalkar,"Cancer remains a major global health concern, accounting for nearly 10 million deaths annually. Despite its complexity and heterogeneity, significant advancements in cancer research over the past two decades have transformed the landscape of cancer diagnosis, treatment, and prevention. Notably, the integration of personalized medicine and technological innovations has led to more precise, effective, and individualized care strategies.",2025-Jul-09,https://pubmed.ncbi.nlm.nih.gov/40628691/,40628691,Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology,10.62958/j.cjap.2025.018,"Department of Pharmaceutical Chemistry, SMBT College of Pharmacy Dhamangaon, Nashik, M.S. India-422403, Affiliated to Savitribai Phule Pune University, India.; Department of Pharmaceutical Chemistry, SMBT College of Pharmacy Dhamangaon, Nashik, M.S. India-422403, Affiliated to Savitribai Phule Pune University, India.; Department of Pharmaceutical Chemistry, SMBT College of Pharmacy Dhamangaon, Nashik, M.S. India-422403, Affiliated to Savitribai Phule Pune University, India.; Department of Pharmaceutical Chemistry, SMBT College of Pharmacy Dhamangaon, Nashik, M.S. India-422403, Affiliated to Savitribai Phule Pune University, India."
PubMed,Corrigendum to 'CT-Based Deep Learning Predicts Prognosis in Esophageal Squamous Cell Cancer Patients Receiving Immunotherapy Combined with Chemotherapy' [Acad Radiol 32/6 (2025) 3397-3409].,Xiaoyu Huang; Yong Huang; Ping Li; Kai Xu,,2025-Jul-07,https://pubmed.ncbi.nlm.nih.gov/40628644/,40628644,Academic radiology,10.1016/j.acra.2025.06.036,"Department of Medical Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China (X.H.).; Department of Medical Oncology, The Second People's Hospital of Hefei, Hefei, China (Y.H.).; Department of Chinese Integrative Medicine Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China (P.L.); Graduate School of Anhui University of Traditional Chinese Medicine, Hefei, China (P.L.).; School of Internet, Anhui University, Hefei, China (K.X.). Electronic address: kaixu@ahu.edu.cn."
PubMed,"Expression of Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) on Malignant but Not Normal Plasma Cells Offers Novel Therapeutic Targets for Patients With Myeloma, Amyloidosis and Other Plasma Cell Dyscrasias.",Mary Sartor; Thomas X Lemarchand; Luise Britz; Jeremy Er; Simon J Harrison; Rosanne Dunn; David J Gottlieb,Kappa myeloma antigen (KMA) and lambda myeloma antigen (LMA) are antigens expressed on the surface of malignant plasma cells (PCs) that may have potential as immunotherapy targets. They arise from conformational epitopes in the constant regions of lipid-associated light chains and are not found on PCs in normal bone marrow (BM).,2025-Jun-05,https://pubmed.ncbi.nlm.nih.gov/40628625/,40628625,"Clinical lymphoma, myeloma & leukemia",10.1016/j.clml.2025.05.022,"Westmead Institute for Medical Research, Westmead, Sydney, New South Wales 2145, Australia.; TPL Path Labs GmbH, StageBio Company, Freiburg im Breisgau 79111, Germany.; TPL Path Labs GmbH, StageBio Company, Freiburg im Breisgau 79111, Germany.; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria 3052, Australia; University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria 3052, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria 3052, Australia.; Haemalogix Ltd, Sydney, New South Wales 2001, Australia.; Westmead Institute for Medical Research, Westmead, Sydney, New South Wales 2145, Australia; Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Westmead, Sydney, New South Wales 2145, Australia; Faculty of Medicine and Health, University of Sydney, New South Wales 2006, Australia. Electronic address: david.gottlieb@sydney.edu.au."
PubMed,IL-18 revives dysfunctional CAR-T cells.,Yan-Ruide Li; Yichen Zhu; Lili Yang,IL-18-armored chimeric antigen receptor (CAR)-engineered T (18.CAR-T) cells have demonstrated enhanced antitumor efficacy in lymphoma patients refractory to conventional CAR-T therapy. Unraveling the mechanisms behind this potent enhancement and mitigating associated toxicities could unlock a new era of next-generation CAR-T therapies with superior effectiveness and broader clinical impact.,2025-Jul-07,https://pubmed.ncbi.nlm.nih.gov/40628538/,40628538,Trends in cancer,10.1016/j.trecan.2025.06.008,"Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: charlie.li@ucla.edu.; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Parker Institute for Cancer Immunotherapy, University of California, Los Angeles, Los Angeles, CA 90095, USA; Goodman-Luskin Microbiome Center, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: liliyang@ucla.edu."
PubMed,Understanding antibody-target antigen interactions and the avidity effect using mathematical modelling.,Luke Heirene; Helen Byrne; Armin Sepp; Eamonn Gaffney; James Yates,"Immunotherapies are designed to exploit the immune system to target pathologies such as cancer. Monoclonal antibodies (mAbs) are an important class of immunotherapies that induce anti-tumour effects. Fundamental to the success of mAbs in cancer treatments are their interactions with target antigens. For example, binding multiple antigens, increasing binding affinity, termed the avidity effect, has been shown to impact treatment outcomes. However, there has been limited theoretical analysis addressing the impacts of antibody-antigen interactions on avidity, potency and efficacy. Hence, our aim is to use a mathematical model to develop insight on these impacts. We analyse an ordinary differential equation model of bivalent, monospecific IgG antibodies binding to membrane antigens and show that the ratio of antibody to antigen number impacts quantities that contribute to mAb potency and efficacy, such as antigen occupancy, and whether an antibody can bind both its antigen-binding arms. A global parameter sensitivity analysis shows that antigen occupancy and the ratio of bound antibody to total antigen number are sensitive to the antibody-antigen binding rates only for high antibody concentrations. We also identify parameter ranges in which the avidity effect is predicted to be large. These results could be used in the preclinical development of mAb therapies by predicting conditions that enhance mAb potency, efficacy and the avidity effect.",2025-Jul,https://pubmed.ncbi.nlm.nih.gov/40628289/,40628289,"Journal of the Royal Society, Interface",10.1098/rsif.2024.0710,"Mathematical Institute, University of Oxford, Oxford, UK.; Mathematical Institute, University of Oxford, Oxford, UK.; Certara UK Limited, Sheffield, UK.; Mathematical Institute, University of Oxford, Oxford, UK.; GSK plc, Stevenage, UK."
PubMed,The costimulatory molecule ICOS limits memory-like properties and function of exhausted PD-1,Etienne Humblin; Isabel Korpas; Nataliya Prokhnevska; Abishek Vaidya; Dan Filipescu; Jiahua Lu; Verena van der Heide; Carlos Alberto de Carvalho Fraga; Tesia Bobrowski; Adam Marks; Matthew D Park; Helder I Nakaya; Emily Bernstein; Brian D Brown; Amaia Lujambio; David Dominguez-Sola; Brad R Rosenberg; Alice O Kamphorst,"During persistent antigen stimulation, CD8",2025-Jul-01,https://pubmed.ncbi.nlm.nih.gov/40628269/,40628269,Immunity,10.1016/j.immuni.2025.06.001,"Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, ISMMS, New York, NY 10029, USA. Electronic address: etienne.humblin@gmail.com.; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, ISMMS, New York, NY 10029, USA.; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, ISMMS, New York, NY 10029, USA.; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, ISMMS, New York, NY 10029, USA.; Tisch Cancer Institute, ISMMS, New York, NY 10029, USA; Department of Oncological Sciences, ISMMS, New York, NY 10029, USA.; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, ISMMS, New York, NY 10029, USA.; Federal University of Alagoas, Arapiraca Campus, Center of Medical Sciences, Bom Sucesso, Alagoas 57309, Brazil.; Department of Microbiology, ISMMS, New York, NY 10029, USA.; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Icahn Genomics Institute, ISMMS, New York, NY 10029, USA.; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, ISMMS, New York, NY 10029, USA.; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo 05508, Brazil; Hospital Israelita Albert Einstein, São Paulo 05620, Brazil.; Tisch Cancer Institute, ISMMS, New York, NY 10029, USA; Department of Oncological Sciences, ISMMS, New York, NY 10029, USA.; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, ISMMS, New York, NY 10029, USA; Tisch Cancer Institute, ISMMS, New York, NY 10029, USA; Icahn Genomics Institute, ISMMS, New York, NY 10029, USA.; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, ISMMS, New York, NY 10029, USA; Department of Oncological Sciences, ISMMS, New York, NY 10029, USA.; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, ISMMS, New York, NY 10029, USA; Department of Oncological Sciences, ISMMS, New York, NY 10029, USA; Department of Pathology, ISMMS, New York, NY 10029, USA.; Department of Microbiology, ISMMS, New York, NY 10029, USA.; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Immunology and Immunotherapy, ISMMS, New York, NY 10029, USA; Tisch Cancer Institute, ISMMS, New York, NY 10029, USA; Department of Oncological Sciences, ISMMS, New York, NY 10029, USA. Electronic address: alice.kamphorst@mssm.edu."
PubMed,Neutralization of acyl coenzyme A binding protein for the experimental prevention and treatment of hepatocellular carcinoma.,Sijing Li; Omar Motiño; Flavia Lambertucci; Jonathan Pol; Hui Chen; Long Pan; Sylvère Durand; Federica Rossin; Claudia Campani; Lucie Poupel; Christophe Klein; Léa Montégut; María Pérez-Lanzón; Gerasimos Anagnostopoulos; Uxia Nogueira-Recalde; Alexandra Cerone; Fanny Aprahamian; Yanbing Dong; Manuela Lizarralde-Guerrero; Enfu Xue; Peng Liu; Liwei Zhao; Hui Pan; Vincent Carbonnier; Sylvie Lachkar; Ester Gloria Saavedra Díaz; Li Sun; Chantal Desdouets; Sabine Colnot; Oliver Kepp; Isabelle Martins; Laurence Zitvogel; Mauro Piacentini; Jean-Charles Nault; Maria Chiara Maiuri; Jessica Zucman-Rossi; Guido Kroemer,"Acyl coenzyme A binding protein (ACBP encoded by diazepam binding inhibitor DBI) is involved in non-malignant liver diseases. Here, we show that DBI mRNA and circulating ACBP/DBI levels are increased in patients with hepatocellular carcinoma (HCC). We investigated its role in hepatocarcinogenesis in mice, inhibiting ACBP/DBI by three methods: (1) inducible whole-body or liver-specific knockout of DBI, (2) a point mutation of the ACBP/DBI receptor (GABRG2), and (3) induction of autoantibodies neutralizing ACBP/DBI. ACBP/DBI plays a major pro-carcinogenic role in HCC induced by intrahepatic transplantation of HCC cell lines, transgenic co-expression of the two oncogenes Myc and Ctnnb1, and chronic challenge with a Western-style diet together with either carbon tetrachloride (CCl",2025-Jul-02,https://pubmed.ncbi.nlm.nih.gov/40628264/,40628264,Cell reports. Medicine,10.1016/j.xcrm.2025.102232,"Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France; Faculté de Médecine, Université de Paris Saclay, Kremlin Bicêtre, Paris, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Team ""Functional Genomics of Solid Tumors"", Centre de Recherche des Cordeliers, Inserm U1138, Université Paris Cité, Sorbonne Université, 75006 Paris, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Department of Biology, University of Rome 'Tor Vergata', Rome, Italy; National Institute for Infectious Diseases IRCCS ""Lazzaro Spallanzani"", 00133 Rome, Italy.; Team ""Functional Genomics of Solid Tumors"", Centre de Recherche des Cordeliers, Inserm U1138, Université Paris Cité, Sorbonne Université, 75006 Paris, France; Department of Experimental and Clinical Medicine, Internal Medicine and Hepatology Unit, University of Firenze, Florence, Italy.; CHICS, Centre de Recherche des Cordeliers, Inserm U1138, Université Paris Cité, Sorbonne Université, Paris, France.; CHICS, Centre de Recherche des Cordeliers, Inserm U1138, Université Paris Cité, Sorbonne Université, Paris, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France; Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Fundación Profesor Novoa Santos, A Coruña, Spain.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France; Faculté de Médecine, Université de Paris Saclay, Kremlin Bicêtre, Paris, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France; Faculté de Médecine, Université de Paris Saclay, Kremlin Bicêtre, Paris, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France; Faculté de Médecine, Université de Paris Saclay, Kremlin Bicêtre, Paris, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France; Departamento de Bioquímica y Biología Molecular, Fisiología, Genética e Inmunología, Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.; Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.; Team Genomic Instability, Metabolism, Immunity and Liver Tumorigenesis Laboratory, Equipe Labellisée LIGUE 2023, Centre de Recherche des Cordeliers, Sorbonne Université, INSERM, Université de Paris, Paris, France.; Team ""Oncogenic functions of β-catenin Signaling in the Liver (ONCOLIV)"", Centre de Recherche des Cordeliers, Equipe Labellisée Par La Ligue Contre le Cancer, Inserm U1138, Université Paris Cité, Sorbonne Université, Paris, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.; Gustave Roussy Cancer Center, ClinicoBiome, 94805 Villejuif, France; Université Paris Saclay, Faculty of Medicine, 94270 Kremlin Bicêtre, France; Inserm U1015, Equipe Labellisée Par La Ligue Contre le Cancer, 94800 Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT), Gustave Roussy, 94805 Villejuif, France.; Department of Biology, University of Rome 'Tor Vergata', Rome, Italy; National Institute for Infectious Diseases IRCCS ""Lazzaro Spallanzani"", 00133 Rome, Italy.; Team ""Functional Genomics of Solid Tumors"", Centre de Recherche des Cordeliers, Inserm U1138, Université Paris Cité, Sorbonne Université, 75006 Paris, France; Liver Unit, Avicenne Hospital, Paris-Seine-Saint-Denis Universitary Hospitals, AP-HP, Bobigny, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Department of Molecular Medicine and Medical Biotechnologies, University of Napoli Federico II, 80131 Naples, Italy. Electronic address: maria-chiara.maiuri@inserm.fr.; Team ""Functional Genomics of Solid Tumors"", Centre de Recherche des Cordeliers, Inserm U1138, Université Paris Cité, Sorbonne Université, 75006 Paris, France; Institut du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.; Université Paris Cité, Sorbonne Université, Inserm U1138, Centre de Recherche des Cordeliers, F-75006 Paris, France; Équipe Labellisée Par La Ligue Contre le Cancer, Institut Universitaire de France, Paris, France; Université Paris-Saclay, INSERM US23 / CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France; Institut du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France. Electronic address: kroemer@orange.fr."
